Precigen is the lead sponsor of 5 current clinical trials in our USA register. 2 are recruiting patients now. The most common phase is Phase 1. The drugs named most often in its trials are Pembrolizumab. The most-studied condition is Recurrent Respiratory Papillomatosis.
| Study | Phase | Status | Start | Registers |
|---|---|---|---|---|
|
Zopa Retreatment and Vector Shedding in Adults With RRP
NCT06538480 · ClinicalTrials.gov ↗ · Recurrent Respiratory Papillomatosis, Papillomavirus Infection, Papillomaviridae
|
Phase 4 | Recruiting | 2024-07 | USA |
|
PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer
NCT06157151 · ClinicalTrials.gov ↗ · Cervical Cancer, HPV-Related Carcinoma, HPV-Related Malignancy
Drug: Pembrolizumab |
Phase 2 | Recruiting | 2025-11 | USA |
|
Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis
NCT04724980 · ClinicalTrials.gov ↗ · Recurrent Respiratory Papillomatosis, Papillomavirus Infections, Papillomaviridae
|
Phase 1/2 | Active, closed | 2021-03 | USA |
|
Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
NCT03907527 · ClinicalTrials.gov ↗ · Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma
|
Phase 1 | Active, closed | 2019-04 | USA |
|
PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS
NCT03927261 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia, Myelodysplastic Syndromes
|
Phase 1 | Active, closed | 2019-05 | USA |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.
Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 5 | 2 |
A trial with sites in more than one country appears in each of those registers.
Precigen is the lead sponsor of 5 current trials on ClinicalTrials.gov in our USA register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of its 5 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Its current trials name 1 drug or biological as interventions. The most frequent are Pembrolizumab (1). The number in brackets is how many of its trials name each drug.
Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.
Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.